Citable company snapshot
Zimmer Biomet's latest SEC-sourced 2026-03-31 period shows $2.09B in revenue and $238.10M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $2.09B | $2.24B | -7.0% |
| xbrl:GrossProfit | Dec 31, 2020 | $1.29B | $1.21B | +6.2% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $373.20M | $154.50M | +141.6% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $238.10M | $139.40M | +70.8% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $359.40M | $517.40M | -30.5% |
| Free Cash Flow (computed) | Mar 31, 2026 | $323.10M | $442.60M | -27.0% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 1, 2026; accession 0001193125-26-201710.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
